CHMP Endorses Monthly Elfabrio Dosing for Fabry Disease
PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 — Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the...
Alzheimer’s Disease Animal Health Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cell Therapy cGxP cGxP compliance Clinical-Stage Biotech Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine Regulatory Affairs regulatory approval regulatory compliance Sanofi targeted therapy venture capital
PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 — Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the...
Allschwil, Switzerland – January 30, 2026 — Idorsia Ltd. announced it will present long-term lucerastat clinical data and kidney...
